Hot flash drug studied for breast cancer survivors, but trial cut short
NCT ID NCT06617455
First seen Mar 03, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it could reduce hot flashes and night sweats in women with breast cancer taking hormone-lowering medications. The trial planned to enroll many participants but was stopped early and only included 9 women. Results are limited, but the drug aims to improve quality of life by easing these common, bothersome symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.